iSpecimen Inc. Interview to Air on the RedChip Money Report® on Bloomberg TV
iSpecimen Inc. (Nasdaq: ISPC) announced that CEO Dr. Christopher Ianelli will be interviewed on The RedChip Money Report® on Bloomberg TV, airing at 7 p.m. ET on August 14, 2021. This program reaches approximately 73 million homes in the U.S. and offers insights on small-cap investing and interviews with industry leaders. The company provides an online marketplace for human biospecimens, linking life scientists with healthcare providers through its cloud-based technology. More details are available at www.ispecimen.com.
- CEO to appear on Bloomberg TV, increasing visibility for ISPC.
- Partnerships with hospitals and labs enhance iSpecimen's marketplace.
- None.
LEXINGTON, Mass., Aug. 12, 2021 /PRNewswire/ -- iSpecimen Inc. (Nasdaq: ISPC), an online marketplace for human biospecimens ("iSpecimen" or the "Company"), today announced that an interview with its CEO and President, Dr. Christopher Ianelli, will air on The RedChip Money Report® on Bloomberg TV, at 7 p.m. Eastern Time (ET) on August 14, 2021. Bloomberg TV is available in an estimated 73 million homes across the United States.
The RedChip Money Report® is produced by RedChip Companies Inc., an international investor relations and media firm with 30 years' experience focused on Discovering Tomorrow's Blue Chips Today™. The RedChip Money Report® delivers insightful commentary on small-cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies.
You can also watch the interview online at https://www.youtube.com/watch?v=ETILpteYxhg.
About iSpecimen
iSpecimen offers an online marketplace for human biospecimens, connecting life scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. For more information about iSpecimen, please visit www.ispecimen.com.
Forward Looking Statements
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are characterized by future or conditional verbs such as "may," "will," "expect," "intend," "anticipate," believe," "estimate" and "continue" or similar words. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information.
Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to the risks factors contained in the Company's filings with the Securities and Exchange Commission, which are available for review at www.sec.gov. Forward-looking statements speak only as of the date they are made. New risks and uncertainties arise over time, and it is not possible for the Company to predict those events or how they may affect the Company. If a change to the events and circumstances reflected in the Company's forward-looking statements occurs, the Company's business, financial condition and operating results may vary materially from those expressed in the Company's forward-looking statements.
Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.
For further information, please contact:
Investor Relations Contact:
Dave Gentry
RedChip Companies Inc.
1-800-RED-CHIP (733-2447)
Or 407-491-4498
Dave@redchip.com
Media Contact:
Kaitlynn Cooney
For iSpecimen
kcooney@brodeur.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ispecimen-inc-interview-to-air-on-the-redchip-money-report-on-bloomberg-tv-301354292.html
SOURCE iSpecimen Inc.
FAQ
When will iSpecimen's CEO be interviewed on Bloomberg TV?
What is the significance of iSpecimen's appearance on The RedChip Money Report?
How can I watch the interview with iSpecimen's CEO?
What services does iSpecimen offer?
